Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute
Articles
Future Directions for Treatment of TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Sequencing Therapies for mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for BRCA+ mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Testing for PD-L1 Expression in mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for Metastatic TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Current Trials for Treatment of Early Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Emerging Data on Biomarkers in ES TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
ICI-Based Therapy in TNBC: Immune-Related Adverse Events
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Early Stage TNBC: Phase 3 IMpassion031 Study
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Key Trials in ICI-Based Therapy for Early Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Role of pCR in Early Stage TNBC Management
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for Early-Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Latest Updated Articles
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
